Core Viewpoint - Kintor Pharmaceutical announced the termination of its subscription to a structured deposit agreement with Bank of China, amounting to RMB 980 million, effective January 7, 2026, without incurring any fees or penalties due to the termination occurring within the investment cooling-off period [1] Group 1 - The company subscribed to a structured deposit agreement with Bank of China for a principal amount of RMB 980 million [1] - The termination of the subscription was made after further consideration and adjustment of the company's financial management strategy [1] - The company will not have to pay any amount or incur any additional costs or penalties due to the termination [1]

Core Viewpoint - The company has announced the termination of its investment in a structured deposit agreement with Bank of China, amounting to RMB 980 million, which will not incur any costs or penalties due to the timing of the termination within the investment cooling-off period [1] Group 1 - The company subscribed to a structured deposit agreement with Bank of China for a principal amount of RMB 980 million [1] - The termination of the subscription was executed on January 7, 2026, after further consideration and adjustment of the company's financial strategy [1] - The termination does not require the company to pay any amount or incur any additional fees or penalties [1]

Group 1 - The company announced the signing of a structured deposit agreement with Bank of China on January 6, 2026, agreeing to subscribe to a structured deposit amounting to RMB 980 million [1] - The company also signed a structured deposit agreement with Bank of Communications on January 6, 2026, agreeing to subscribe to a structured deposit amounting to RMB 400 million [1]

Core Viewpoint - The company, Kelun-Biotech (06990.HK), has entered into structured deposit agreements with two banks, indicating a strategic move to manage its cash reserves effectively [1] Group 1: Structured Deposit Agreements - The company has agreed to subscribe to a structured deposit with Bank of China amounting to RMB 980 million [1] - Additionally, the company has entered into a structured deposit agreement with China Construction Bank for RMB 400 million [1]

Group 1 - Company Kelong Botai Biotech-B (06990) announced the signing of a structured deposit agreement with Bank of China on January 6, 2026, agreeing to subscribe to a structured deposit amounting to RMB 980 million [1] - On the same date, the company also entered into a structured deposit agreement with China Transportation Bank, agreeing to subscribe to a structured deposit of RMB 400 million [1]